Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Click here to view

WORLDSymposium 2024

Presentation: Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)
February 5th, 2024
Poster: Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)
February 5th, 2024
Presentation: A 3-month gene therapy single-dose IV administration pharmacology and safety study with ST-920 (isaralgagene civaparvovec) for Fabry disease in mice
February 5th, 2024
Poster: A 3-month gene therapy single-dose IV administration pharmacology and safety study with ST-920 (isaralgagene civaparvovec) for Fabry disease in mice
February 5th, 2024
Poster: Anti-AAV6 antibody assay for patient enrollment supporting ST-920 phase 1/2 study for Fabry disease
February 5th, 2024